A5045977047- Multiple Sclerosis Research Studies
- Immunotherapy and Immune Responses
- Polyomavirus and related diseases
- T-cell and B-cell Immunology
- Peripheral Neuropathies and Disorders
- Immune Cell Function and Interaction
- Rheumatoid Arthritis Research and Therapies
- Acute Lymphoblastic Leukemia research
- CAR-T cell therapy research
- SARS-CoV-2 and COVID-19 Research
- Cytokine Signaling Pathways and Interactions
- Fungal Plant Pathogen Control
- Systemic Lupus Erythematosus Research
- Immune Response and Inflammation
- Autoimmune and Inflammatory Disorders Research
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Immunodeficiency and Autoimmune Disorders
- Cystic Fibrosis Research Advances
- Atherosclerosis and Cardiovascular Diseases
- Brain Metastases and Treatment
- Mathematical Biology Tumor Growth
- RNA Interference and Gene Delivery
- Psoriasis: Treatment and Pathogenesis
- Long-Term Effects of COVID-19
- Systemic Sclerosis and Related Diseases
Biogen (United States)
2017-2025
Ibero American University
2018-2019
Biogen (Switzerland)
2019
Center for Value Based Medicine (United States)
2019
The University of Texas Southwestern Medical Center
2007-2013
Southwestern Medical Center
2007-2013
The radiologically isolated syndrome (RIS) represents the earliest detectable pre-clinical phase of multiple sclerosis (MS). This study evaluated impact therapeutic intervention in preventing first symptom manifestation at this stage disease spectrum.We conducted a multi-center, randomized, double-blinded, placebo-controlled involving people with RIS. Individuals without clinical symptoms typical MS but incidental brain MRI anomalies consistent central nervous system (CNS) demyelination were...
Objectives In a prospective phase IV trial of the first-line oral treatment dimethyl fumarate (DMF), we examined dynamics neurofilament light (NFL) chain in serum, plasma and cerebrospinal fluid (CSF) samples collected over 12 months from relapsing-remitting multiple sclerosis (RRMS) patients. NFL changes were related to disease activity. Methods We levels by single-molecule array 88 CSF, 348 131 sera treatment-naïve RRMS patients (n=52), healthy controls (n=23) placebo group matched age,...
Diroximel fumarate (DRF) is an oral for relapsing multiple sclerosis (MS) with the same active metabolite as dimethyl (DMF). DRF has a safety/efficacy profile similar to DMF but improved gastrointestinal (GI) tolerability and low (< 1%) treatment discontinuation due GI adverse events (AEs). Efficacy safety outcomes in patients who switched from other disease-modifying therapies (DMTs) have not been evaluated. EVOLVE-MS-1 ongoing, 2-year, open-label, phase 3 study of adults...
BackgroundPrevious real-world comparative research of MS disease modifying therapies (DMTs) in the overall population has suggested dimethyl fumarate (DMF) to be comparable fingolimod (FTY) and more efficacious than teriflunomide (TERI) reducing relapses. However, there is limited evidence patients switching from platform DMTs US. The objective study was compare annualized relapse rate (ARR) risk who have switched a therapy DMF, FTY, or TERI.MethodsMS (18–65 years old) initiating an oral DMT...
Delayed-release dimethyl fumarate (DMF) may be a therapeutic option for patients with relapsing-remitting multiple sclerosis (RRMS) who are treated natalizumab and require change in therapy. However, there is limited information regarding predictors of favorable treatment outcomes switching from to DMF. Clinical practices sequencing protocols vary. Herein, we present the clinical results, including annualized relapse rate (ARR) risk relapse, phase 4 retrospective observational study RRMS...
Multiple sclerosis (MS) is an immune-mediated demyelinating disease of the CNS, and CD8 T cells are predominant cell population in MS lesions. Given that transfer CNS-specific results attenuated clinical C57BL/6 mice with immunization-induced experimental autoimmune encephalomyelitis (EAE), we investigated cellular targets mechanisms autoreactive regulatory cells. In this study report myelin oligodendrocyte glycoprotein peptide (MOG35-55)-induced could also attenuate adoptively transferred,...
Delayed-release dimethyl fumarate (DMF) demonstrates sustained efficacy and safety for relapsing forms of MS. Absolute lymphocyte count (ALC) is reduced initially, then stabilizes on treatment.PROCLAIM, a 96-week, prospective, open-label, phase 3b study, assessed subsets immunoglobulin (Ig) levels during 48 96 weeks (W) DMF treatment.Patients received 240 mg BID. Endpoints: subset changes (primary); Ig isotypes ALC (secondary); adverse events relationship between ARR/EDSS (exploratory);...
Switching disease-modifying therapy (DMT) may be considered for relapsing–remitting multiple sclerosis (RRMS) if a patient's current is no longer optimal. This was particularly important during the recent COVID-19 pandemic because of considerations around immune deficiency and impaired vaccine response associated with B cell-depleting DMTs. real-world, single-center study aimed to evaluate change or decline in functional ability overall disease stability people RRMS who were switched from...
The exact mechanism of glatiramer acetate (GA, Copaxone®), an FDA-approved immunomodulatory therapy for multiple sclerosis (MS), remains unclear after decades research. Previously, we have shown that GA MS induces CD8+ T cell responses can potentially suppress pathogenic CD4+ responses. Using a murine model MS, experimental autoimmune encephalomyelitis (EAE), now demonstrate cells are necessary in mediating the therapeutic effects GA. Further, adoptive transfer GA-induced resulted...
Aim: Anti-CD20 monoclonal antibodies and fumarates are common multiple sclerosis (MS) disease-modifying therapies (DMTs). Data on switching from anti-CD20s to other DMTs limited. This retrospective, observational study of the US Komodo Health Sentinel claims database aimed evaluate a de-escalation strategy in real-world cohort, comparing clinical characteristics, relapses, healthcare encounters (HCEs) costs (HCCs) between patients aged ≥18 years with stable MS who switched (‘Switchers’)...
Introduction Black or African American (black/AA) patients with multiple sclerosis (MS) are reported to exhibit greater disease severity compared non-black non-AA patients. Whether differences exist in response MS disease-modifying therapies remains uncertain, as clinical trials have included low numbers of non-white We evaluated real-world safety and effectiveness dimethyl fumarate (DMF) on activity black/AA Methods ESTEEM is an ongoing, 5-year, multinational, prospective study evaluating...
Some multiple sclerosis (MS) disease-modifying therapies (DMTs) impair responses to vaccines, emphasizing the importance of understanding COVID-19 vaccine immune in people with MS (PwMS) receiving different DMTs. This prospective, open-label observational study enrolled 45 participants treated natalizumab (n = 12), ocrelizumab 16), fumarates (dimethyl fumarate or diroximel fumarate, n 11), interferon beta 6); ages 18–65 years inclusive; stable on DMT for at least 6 months. Responder rates,...
In EVOLVE-MS-1 (NCT02634307), mean absolute lymphocyte count (ALC) on diroximel fumarate (DRF) declined from baseline by approximately 28% in year 1, then stabilized, similar to ALC decline observed with dimethyl (DMF). Prior studies reported that clinical efficacy of DMF was not substantially different patients and without lymphopenia. EVOLVE-MS-1—an open-label, 96-week, phase 3 study—assessed DRF safety exploratory relapsing–remitting multiple sclerosis. This study analyzes...
Introduction Compared with the non-Hispanic/non-Latino population, Hispanic/Latino patients multiple sclerosis (MS) are reported to exhibit greater disease severity. Geographical location and genetics play a role in differences observed across subpopulations. We evaluated real-world safety effectiveness of dimethyl fumarate (DMF) on MS activity patients. Methods ESTEEM is an ongoing, 5-year, multinational, prospective study evaluating long-term DMF MS. This interim analysis included newly...
Persistence to multiple sclerosis (MS) disease-modifying therapy is fundamental for maximal treatment outcomes. Diroximel fumarate (DRF) approved in the USA relapsing MS. Following oral administration, DRF metabolized monomethyl fumarate, active metabolite of dimethyl (DMF). showed clinically significant improvements gastrointestinal (GI) tolerability versus DMF a head-to-head clinical trial; however, real-world persistence/adherence has not been assessed. We evaluated DRF-treated patients...